MCID: MCN008
MIFTS: 38

Mucinous Cystadenocarcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mucinous Cystadenocarcinoma

MalaCards integrated aliases for Mucinous Cystadenocarcinoma:

Name: Mucinous Cystadenocarcinoma 11 14 16 75
Cystadenocarcinoma, Mucinous 43 71
Pseudomucinous Cystadenocarcinoma 11
Cystadenocarcinoma Mucinous 53

Classifications:



External Ids:

Disease Ontology 11 DOID:3603
MeSH 43 D018282
NCIt 49 C3776
SNOMED-CT 68 79143006
UMLS 71 C0206699

Summaries for Mucinous Cystadenocarcinoma

Disease Ontology: 11 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue, with a capsulated structure and mucus-producing cells.

MalaCards based summary: Mucinous Cystadenocarcinoma, also known as cystadenocarcinoma, mucinous, is related to ovarian mucinous cystadenocarcinoma and cystadenocarcinoma. An important gene associated with Mucinous Cystadenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and Adhesion. The drugs Bevacizumab and Immunoglobulins, Intravenous have been mentioned in the context of this disorder. Affiliated tissues include pancreas, appendix and ovary, and related phenotypes are neoplasm and digestive/alimentary

Wikipedia: 75 Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Mucinous Cystadenocarcinoma

Diseases related to Mucinous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 515)
# Related Disease Score Top Affiliating Genes
1 ovarian mucinous cystadenocarcinoma 32.2 SERPINA3 CEACAM5 AFP
2 cystadenocarcinoma 31.0 SERPINA3 MUC16 MUC1 KRT7 KRAS CEACAM5
3 pancreatic cystadenocarcinoma 30.8 KRAS CEACAM5
4 appendix adenocarcinoma 30.6 SMAD4 KRT7 KRT20 KRAS HRAS CEACAM5
5 mucoepidermoid carcinoma 30.4 SERPINA3 MUC1 KRT7
6 small cell carcinoma 30.4 KRT7 KRT20 CEACAM5
7 goblet cell carcinoid 30.4 KRT20 CEACAM7
8 microcystic adenoma 30.3 MUC1 CEACAM5
9 dermoid cyst of ovary 30.3 CEACAM5 AFP
10 epulis 30.2 SERPINA3 KRT7
11 clear cell adenocarcinoma 30.2 SMAD4 MUC16 KRT7
12 benign mesothelioma 30.2 KRT7 KRT20 CEACAM5
13 papillary cystadenocarcinoma 30.2 SERPINA3 MUC16 KRT7 KRT20
14 papillary carcinoma 30.2 MUC1 KRT7 KRT20
15 breast ductal carcinoma 30.1 TFF1 SMAD4 MUC1 KRT7
16 small cell cancer of the lung 30.1 KRT7 KRT20 CEACAM5
17 serous cystadenocarcinoma 30.1 MUC16 KRT7 KRAS HRAS
18 ovarian cyst 30.0 MUC16 MUC1 CEACAM7 CEACAM5 AFP
19 chronic pyelonephritis 30.0 SERPINA3 KRT7
20 ovarian cystadenocarcinoma 30.0 SMAD4 SERPINA3 MUC16 MUC1 KRAS HRAS
21 benign teratoma 30.0 KRT7 KRT20 CEACAM5 CDX2 AFP
22 dysgerminoma 29.9 MUC1 KRT7 KRT20 AFP
23 pseudomyxoma peritonei 29.9 MUC16 MUC1 KRT7 KRT20 KRAS CEACAM5
24 angiosarcoma 29.8 SERPINA3 MUC1 KRAS
25 intestinal obstruction 29.8 KRT7 KRT20 CEACAM5 CDX2
26 cholecystolithiasis 29.7 CEACAM5 AFP
27 cystic teratoma 29.7 MUC1 KRT7 KRT20 CEACAM5 CDX2 AFP
28 cervical squamous cell carcinoma 29.7 SMAD4 KRAS CEACAM5
29 neuroendocrine carcinoma 29.7 MUC1 KRT7 KRT20 AFP
30 polycystic liver disease 1 with or without kidney cysts 29.7 MUC16 MUC1 KRT7 KRT20 CEACAM5 CEACAM3
31 mesothelioma, malignant 29.7 MUC16 MUC1 KRT7 KRT20 CEACAM5 CEACAM3
32 pancreatic ductal adenocarcinoma 29.6 SMAD4 SERPINA3 KRAS HRAS
33 cystadenoma 29.6 SERPINA3 MUC16 MUC1 KRT7 KRT20 CEACAM5
34 endodermal sinus tumor 29.6 MUC16 KRT7 CEACAM5 AFP
35 mucinous ovarian cystadenoma 29.6 KRT7 KRT20 CEACAM5 CDX2 AFP
36 krukenberg carcinoma 29.6 KRT7 KRT20 CEACAM5 CDX2 AFP
37 mucinous adenocarcinoma 29.5 SMAD4 MUC1 KRT7 KRT20 KRAS HRAS
38 ovarian mucinous adenocarcinoma 29.5 SERPINA3 KRT7 KRT20 CEACAM5 CDX2
39 acinar cell carcinoma 29.5 SMAD4 SERPINA3 KRT7 AFP
40 obstructive jaundice 29.5 SERPINA3 MUC16 KRT7 CEACAM5 AFP
41 bladder urachal carcinoma 29.4 KRT7 KRAS HRAS CDX2
42 mature teratoma 29.4 KRT7 CEACAM5 CDX2 AFP
43 teratoma 29.4 MUC1 KRT7 KRT20 KRAS CEACAM5 CDX2
44 gastrointestinal stromal tumor 29.4 SERPINA3 KRAS HRAS CEACAM5
45 ovarian mucinous neoplasm 29.3 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
46 rhabdomyosarcoma 29.3 SMAD4 KRT7 KRAS HRAS CEACAM5
47 adenocarcinoma 29.3 SMAD4 MUC1 KRT7 KRT20 KRAS HRAS
48 appendiceal neoplasm 29.2 MIR4328 KRT7 KRAS HRAS CEACAM5 CDX2
49 adenoma 29.2 SMAD4 MUC1 KRT7 KRT20 KRAS HRAS
50 squamous cell carcinoma 29.2 SMAD4 MUC1 KRT7 KRAS HRAS CEACAM5

Graphical network of the top 20 diseases related to Mucinous Cystadenocarcinoma:



Diseases related to Mucinous Cystadenocarcinoma

Symptoms & Phenotypes for Mucinous Cystadenocarcinoma

MGI Mouse Phenotypes related to Mucinous Cystadenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.56 AFP CDX2 CEACAM5 HRAS KRAS MUC1
2 digestive/alimentary MP:0005381 9.17 CDX2 CEACAM5 HRAS KRAS MUC1 SMAD4

Drugs & Therapeutics for Mucinous Cystadenocarcinoma

Drugs for Mucinous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
2 Immunoglobulins, Intravenous Phase 3
3 Immunoglobulins Phase 3
4 Immunoglobulin G Phase 3
5 Angiogenesis Inhibitors Phase 3
6 Antibodies, Monoclonal Phase 3
7 Antibodies Phase 3
8 Antineoplastic Agents, Immunological Phase 3
9 Endothelial Growth Factors Phase 3
10 Mitogens Phase 3
11
Sargramostim Approved, Investigational Phase 2 123774-72-1
12
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
13
Belinostat Approved, Investigational Phase 2 414864-00-9, 866323-14-0 53437714 6918638
14
Nivolumab Approved Phase 2 946414-94-4
15
Ipilimumab Approved Phase 2 477202-00-9
16
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
17
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
18
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
19
Lenograstim Approved, Investigational Phase 2 135968-09-1
20
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
21
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
22
Molgramostim Investigational Phase 2 99283-10-0
23
MK-1775 Investigational Phase 2 955365-80-7 24856436
24 Protein Kinase Inhibitors Phase 2
25 Histone Deacetylase Inhibitors Phase 2
26 Immune Checkpoint Inhibitors Phase 2
27 Antiviral Agents Phase 2
28 Immunosuppressive Agents Phase 2
29 Immunologic Factors Phase 2
30 Albumin-Bound Paclitaxel Phase 2
31 Antimitotic Agents Phase 2
32 Tubulin Modulators Phase 2
33 topoisomerase I inhibitors Phase 2
34 Antirheumatic Agents Phase 2
35 Alkylating Agents Phase 2
36 Antineoplastic Agents, Alkylating Phase 2
37 Adjuvants, Immunologic Phase 2
38
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
39
Denileukin diftitox Approved, Investigational Phase 1 173146-27-5
40
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
41
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
42
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
43
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 43805 11947679 6857599
44
Ethanol Approved Phase 1 64-17-5 702
45
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
46
Paclitaxel poliglumex Experimental, Investigational Phase 1 263351-82-2
47
Veliparib Investigational Phase 1 912444-00-9 11960529
48 Interleukin-2 Phase 1
49 Analgesics, Non-Narcotic Phase 1
50 Analgesics Phase 1

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
2 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
3 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
4 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
5 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
6 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
7 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
8 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
9 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
10 A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
11 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00079430 Phase 1 paclitaxel;carboplatin
12 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
13 PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
14 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
15 Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer Completed NCT00357448 Phase 1
16 A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
17 A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
18 A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
19 A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors Terminated NCT01233505 Phase 1 veliparib;capecitabine;oxaliplatin
20 EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Terminated NCT01525706 Phase 1 Ethanol and Paclitaxel Injection
21 Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by Quantitative Real Time MEMO-PCR Unknown status NCT02130648
22 A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT01080521
23 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1
24 Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy Terminated NCT01275664 Aprepitant;Carboplatin;Cisplatin;Dexamethasone;Granisetron Transdermal Patch

Search NIH Clinical Center for Mucinous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, mucinous

Genetic Tests for Mucinous Cystadenocarcinoma

Anatomical Context for Mucinous Cystadenocarcinoma

Organs/tissues related to Mucinous Cystadenocarcinoma:

MalaCards : Pancreas, Appendix, Ovary, Endothelial, Breast, Lymph Node, Liver

Publications for Mucinous Cystadenocarcinoma

Articles related to Mucinous Cystadenocarcinoma:

(show top 50) (show all 738)
# Title Authors PMID Year
1
Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature. 53 62
17993730 2007
2
[Two cases of appendicial mucinous cystadenocarcinoma with raised serum and mucin carcinoembryonic antigen (CEA) concentration]. 53 62
12833863 2003
3
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. 53 62
9852392 1999
4
Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. 53 62
7543441 1995
5
Serum and tissue measurements of CA72-4 in ovarian cancer patients. 53 62
8381375 1993
6
CA54/61 as a marker for epithelial ovarian cancer. 53 62
1737381 1992
7
A case of primary mucinous cystadenocarcinoma of the appendix with elevated serum carcinoembryonic antigen (CEA). 53 62
2101417 1990
8
Urachal mucinous cystadenocarcinoma: A case report. 62
36280482 2022
9
[A Case Report of Psoas Abscess Formation Caused by Mucinous Cystadenocarcinoma]. 62
36046978 2022
10
A case of pancreatic mucinous cystadenocarcinoma with malignant ascites without recurrence for more than 8 years after surgery. 62
35546381 2022
11
A case of giant mucinous cystadenocarcinoma of the liver with intraoperative bleeding. 62
35637115 2022
12
Urachal Carcinoma, An Unusual Possibility of Hematuria; Case Report and Literature Review. 62
36010242 2022
13
Giant ovarian mucinous cystadenocarcinoma: A case report. 62
35846900 2022
14
[Mixed mucinous cystadenocarcinoma and columnar cell mucinous carcinoma of the breast with axillary lymph node metastases: report of a case]. 62
35673736 2022
15
Computed Tomography and Clinical Analysis of Ovarian Mucinous Tumors in Adolescent Patients. 62
34728347 2022
16
Giant Mucinous Cystadenocarcinoma of the Ovary with Cavitary Metastases to Lungs in a Postmenopausal Woman: A Rare Presentation. 62
35746916 2022
17
Primary Breast Mucinous Cystadenocarcinoma and Review of Literature. 62
35464581 2022
18
Mucinous cystadenocarcinoma of the breast: a new entity with broad differentials-a case report. 62
35224708 2022
19
Pathological Features of Ovarian Tumors, Diagnosed at a Tertiary Care Hospital in Afghanistan: A Cross-sectional Study. 62
36465710 2022
20
Papillary lesions of the breast. 62
34734332 2022
21
Cancer-specific survival and metastasis in pancreatic mucinous cystadenocarcinoma: A SEER-based cohort study. 62
36338678 2022
22
CT classification model of pancreatic serous cystic neoplasms and mucinous cystic neoplasms based on a deep neural network. 62
34636931 2022
23
Single-incision laparoscopic surgery compared to conventional laparoscopic surgery for appendiceal mucocele: a series of 116 patients. 62
33502619 2022
24
[Breast mucinous cystadenocarcinoma: report of a case]. 62
34719180 2021
25
Surgical management and outcomes of paediatric ovarian tumours-a 25-year UK single centre experience. 62
34170394 2021
26
Primary Mucinous Cystadenocarcinoma of the Breast: A Rare Case Report With Review of Literature. 62
33635116 2021
27
An unusual large protuberant lesion of the ascending colon mucosa caused by mucinous cystadenocarcinoma of the appendix. 62
34023391 2021
28
Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis. 62
33814494 2021
29
Genetic profile of primary mucinous cystadenocarcinoma of the breast-A case report. 62
34180564 2021
30
Umbilical sparing robotic partial cystectomy for localized urachal adenocarcinoma: A case report. 62
34703767 2021
31
Obstructive Jaundice Caused by Mucinous Cystic Tumor of Gallbladder: A Case Report and Literature Review. 62
34447691 2021
32
Mucinous cystadenocarcinoma of pancreas mimicking gastrointestinal stromal tumor of stomach: Case report. 62
34343789 2021
33
Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease? 62
34257114 2021
34
[Updated WHO classification of tumors of the breast: the most important changes]. 62
33822251 2021
35
miR‑224‑5p regulates the proliferation, migration and invasion of pancreatic mucinous cystadenocarcinoma by targeting PTEN. 62
33760113 2021
36
[Mucinous Cystadenocarcinoma with a Sarcomatous Component Arising from the Sigmoid Mesocolon-A Case Report]. 62
33976051 2021
37
Choroidal mass secondary to mucinous cystadenocarcinoma of ovary in a young woman: a life-threatening metastasis. 62
34179588 2021
38
Mucinous cystadenocarcinoma of breast in a 69-year-old woman with positive hormone receptors, the first case reported. 62
34760102 2021
39
Breast Metastases Secondary to Primary Pancreatic Mucinous Cystadenocarcinoma: A Case Report. 62
33370036 2021
40
Pulmonary Mucinous Cystadenoma - A Rare Pathology. 62
33402519 2021
41
Primary retroperitoneal mucinous cystadenocarcinoma in pregnancy - case report. 62
34465113 2021
42
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review. 62
31084406 2020
43
Autophagy promotes malignant migration and invasion via miR-224-5p/BCL2 in pancreatic mucinous cystadenocarcinoma MCC1 cells. 62
33029204 2020
44
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. 62
33362915 2020
45
Mucinous cystadenocarcinoma of the spleen - a very rare case of a primary splenic MCN. 62
34057428 2020
46
Mucinous cystadenocarcinoma of the oral tongue: malignant transformation from a mucinous cystadenoma? 62
33127690 2020
47
Primary retroperitoneal mucinous cystadenocarcinoma with transition from the mesothelium. 62
33392473 2020
48
Pulmonary mucinous cystadenocarcinoma: an unusual presentation and literature review. 62
32675126 2020
49
Clinical diagnosis and management of pancreatic mucinous cystadenoma and cystadenocarcinoma: Single-center experience with 82 patients. 62
32699579 2020
50
A Rare Case of Incidental Urachal Mucinous Cystadenocarcinoma. 62
32523832 2020

Variations for Mucinous Cystadenocarcinoma

Expression for Mucinous Cystadenocarcinoma

Search GEO for disease gene expression data for Mucinous Cystadenocarcinoma.

Pathways for Mucinous Cystadenocarcinoma

GO Terms for Mucinous Cystadenocarcinoma

Sources for Mucinous Cystadenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....